All News
Differentiating AS from OCI using CT scanning by Terrier et al showed that Subchondral Bone Attenuation Coefficient (SBAC) was higher in OCI than AS with a threshold of >7500 Hounslow Units discriminating the two conditions #EULAR2022 @RheumNow POS0126 https://t.co/8MdSe3Dqp7
Dr. Antoni Chan synovialjoints ( View Tweet)
Measuring liver stiffness (LS) by transient elastography can detect and follow up hepatic involvement in AL amyloidosis as radiolabelled SAP scan not widely available by Brunger et al . Higher LS in with liver involvement vs heart/no involvement #EULAR2022 @RheumNow POS0124
Dr. Antoni Chan synovialjoints ( View Tweet)
GM-CSF increased in patients with active ankylosing spondylitis, correlates with disease activity, not duration. TNFi does not affect GM-CSF levels. Could explain efficacy of JAKinibs and response for residual inflammation during TNF blockade.
@RheumNow #EULAR2022 ABST#OP0107
Robert B Chao, MD doctorRBC ( View Tweet)
Depression was the most prevalent comorbidity (31%), hypertension (26%) and uveitis the most common EMM (30%) in AS from the PSOAS cohort by @rheum_cat .
Five clusters identified with depression and hypertension groups having higher disease activity #EULAR2022 @RheumNow OP0154 https://t.co/dpqaFD4Qzw
Dr. Antoni Chan synovialjoints ( View Tweet)
Check out my thoughts on this work on PMR's immunol signature:
video: https://t.co/7aTJMsR9Te
article: https://t.co/PTDHPv7gZC
for @RheumNow's #EULAR2022 coverage
PS just had a quick chat with @jiemy_william, so much exciting stuff to come from @VasculitisUMCG @ElisabethBrouw3! https://t.co/l94F5qAgDI
Links:
David Liew drdavidliew ( View Tweet)
#POS0716 #EULAR2022 Systematic review and meta-analysis of 7 studies (i.e. only 1 x proof of concept RCT) showed high SRI-4 response rate (82%) in #lupus patients treated on IL2. Injection reaction (33%) and Fever (24%). Promising and definitive RCT is needed @RheumNow https://t.co/BBcgt11yNT
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Congenital malformations after intra-uterine exposure to non-TNFi when compared to certolizumab showed vedolizumab and belimumab were associated with higher CMs. Vedolizumab showed specific CM pattern (corpus collosum agenesis).
@RheumNow #EULAR2022 ABST#OP0129 https://t.co/wgRlm9QLgW
Robert B Chao, MD doctorRBC ( View Tweet)
#EULAR2022
Ultrasound may be used to evaluate patients with RA (POS1393) and SSc (POS1394)
👁️Look for B-lines and pleural irregularity
Will require training of MSKUS rheumatologists, but another potential application of US in clinical practice
@RheumNow @MymaAlbaydaMD @USSONAR_Rh https://t.co/qtnBviKA3w
Eric Dein ericdeinmd ( View Tweet)
#POS0713 #EULAR2022 Exploratory analyses from Phase 2 RCT showed numerically more patients treated with BIIB059, a BDCA2 inhibitor achieved a clear (CLASI of 0-1) and almost clear cutaneous #lupus (CLASI 0-3). Looking forward to Phase 3 results in the next few years @RheumNow https://t.co/dDbwYCx7zT
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2022 annual meeting is sponsored in part by Bristol-Myers Squibb. All content is chosen by RheumNow & its faculty.
Dr. John Cush RheumNow ( View Tweet)
Watch: EULAR 2022 - Day 1 Faculty Recap Pane
Drs. Jack Cush, Eric Dein and Kathryn Dao discuss highlights from day 1 at #EULAR2022 - Guidelines, Lupus, and more.
https://t.co/OBLt7dOMa3 https://t.co/lHmEOIFIGa
Links:
Dr. John Cush RheumNow ( View Tweet)
No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest.
@RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
Robert B Chao, MD doctorRBC ( View Tweet)
“Post-exertional fatigue is real (in #LongCovid), not their fault. Validate their symptoms. Pain is secondary.”- Dr. @LCalabreseDO #EULAR2022 @rheumnow https://t.co/hDvxJfb14f
TheDaoIndex KDAO2011 ( View Tweet)
#POS0721 #EULAR2022 Are Aspirin + LMWH enough to prevent Adverse Pregnancy Outcomes (preterm, pregnancy loss, eclampsia) in High Risk Triple Antiphospholipid abs+ve + Low C3/C4? An Italian study of 128 patients said NO. Add Hydroxychloroquine @RheumNow https://t.co/927sZoHZEj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
JAKi for nonradiographic axSpA
One area of continued interest for many rheumatologists is the field of non-radiographic axial spondyloarthritis. And the question of the utility of JAK inhibitors for the treatment of axSpA has been on the rise.
https://t.co/xq8ICyKKv0 https://t.co/o2iUgyU60A
Links:
Dr. John Cush RheumNow ( View Tweet)
Germano et al. Temporal artery abnormality on clinical exam predicts biopsy + . Arterial thickening and reduced pulse strongest predictors @RheumNow #EULAR2022 POS0820 https://t.co/Rs36ALSoJb
Richard Conway RichardPAConway ( View Tweet)
Merola et al. Risankizumab on MDA and DAPSA in KEEPsAKE 1 and 2. Week 24 MDA 25.0/25.6% vs 10.2/11.4%. DAPSA LDA+REM 41.2/36.8% week 24, 59.2/44.6% week 52 @RheumNow #EULAR2022 POS1029 https://t.co/Uz7kA76pMH
Richard Conway RichardPAConway ( View Tweet)
About 50% w/ #LongCOVID has persistent Sx's at 6 mos (fatigue, muscle weakness, insomnia, anxiety, depression, dyspnea). Risks: female, obesity &prior mechan ventilation. Interestingly, the pts have inc CRP levels. DLCO is low. – Prof R Mostard #EULAR2022 @rheumnow https://t.co/8jCEObjf5I
TheDaoIndex KDAO2011 ( View Tweet)
Risk factors associated with non-remission/LDA in PsA pts:
Baseline TJC>3, SJC>5
CRP>10
HAQ>0.5
enthesitis/dactylitis
BMI>30
sDMARD use
@RheumNow #EULAR2022 ABST#POS0080
Robert B Chao, MD doctorRBC ( View Tweet)
Sex differences in PsA disease expression and treatment. Treatment efficacy and retention rates lower among female PsA pts initiating first TNFi. Women presented with higher 28 TJC and PRO at baseline as well..
@RheumNow #EULAR2022 ABST#POS0077 https://t.co/yV11kCN2bZ
Robert B Chao, MD doctorRBC ( View Tweet)